This biotech stock is an 'oncology powerhouse' with 40% upside, …

5 days ago · The firm's 12-month price target on the Nasdaq-traded shares of the German company is $172.

40%
OFF

This Biotech Stock Is An 'oncology Powerhouse' With 40% Upside, …

2 weeks from now

5 days ago · The firm's 12-month price target on the Nasdaq-traded shares of the German company is $172.

cnbc.com

$172
OFF

BioNTech Initiated With A Buy At Truist - Markets Insider

2 weeks from now

6 days ago · Truist initiated coverage of BioNTech (BNTX) with a Buy rating and $172 price target BioNTech is an oncology company “at heart, even though it was the COVID vaccine that made …

businessinsider.com

40%
OFF

Truist Rates BioNTech A Buy, Citing 40% Upside Potential With Key …

2 weeks from now

6 days ago · The analyst from Truist Securities pointed out that the potential upside to their $172 price target represents approximately a 40% increase from current levels. This optimistic …

investing.com

$132.00
OFF

BioNTech (NASDAQ:BNTX) Earns Buy Rating From Analysts At …

2 weeks from now

5 days ago · TD Cowen decreased their target price on shares of BioNTech from $132.00 to $122.00 and set a "hold" rating for the company in a research report on Tuesday, November …

marketbeat.com

$172
OFF

Truist Initiates BioNTech At Buy With $172 Price Target

2 weeks from now

5 days ago · Truist Initiates BioNTech at Buy With $172 Price Target 06:30am: MT European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading Jan. 07: …

marketscreener.com

81%
OFF

BioNTech (BNTX) Stock Forecast And Price Target 2025 - MarketBeat

2 weeks from now

6 days ago · The highest price target for BNTX is $172.00, ... Truist Financial. 2 of 5 stars : Initiated Coverage: Buy: $172.00 +40.81%: 12/11/2024: Wells Fargo & Company. 3 of 5 stars: …

marketbeat.com

$172
OFF

Promising Oncology Pipeline And Financial Strength Drive …

2 weeks from now

6 days ago · Overall, Goonewardene’s valuation model, which incorporates future cash flows and a discounted cash flow approach, supports a Buy rating with a price target of $172, reflecting …

businessinsider.com

40%
OFF

Truist Rates BioNTech A Buy, Citing 40% Upside Potential With Key …

2 weeks from now

6 days ago · On Friday, Truist Securities began coverage on BioNTech shares (NASDAQ: BNTX) with a Buy rating, accompanied by a price target set at $172.00.The securities firm's analysis …

investing.com

41%
OFF

Truist Securities Gives BioNTech A Buy Rating With A Price Target Of ...

2 weeks from now

5 days ago · Truist Securities has initiated coverage of BioNTech SE, giving it a buy rating and a 12-month price target of $172 per share. This represents a potential increase of nearly 41% …

newsminimalist.com

47%
OFF

BNTX Stock Price Target | BioNTech Analyst Ratings

2 weeks from now

Analyst Price Target for BNTX ... The average price target is $142.72, with a high forecast of $172.00 and a low forecast of $122.00. The average price target represents a 25.47% upside …

pricetargets.com

22%
OFF

Truist Securities Initiates Coverage Of BioNTech SE - Depositary

2 weeks from now

6 days ago · Analyst Price Forecast Suggests 14.22% Upside As of December 23, 2024, the average one-year price target for BioNTech SE - Depositary Receipt is $139.52/share. The …

msn.com

$172
OFF

Truist Initiates BioNTech At Buy With $172 Price Target

2 weeks from now

5 days ago · -- BioNTech's US stock has an average rating of overweight and mean price target of $137.73, according to analysts polled by FactSet. ...

marketscreener.com

$172
OFF

Truist Securities Initiates Coverage On BioNTech With Buy Rating ...

2 weeks from now

6 days ago · Truist Securities analyst Asthika Goonewardene initiates coverage on BioNTech (NASDAQ:BNTX) with a Buy rating and announces Price Target of $172.

sahmcapital.com

FAQs about This biotech stock is an 'oncology powerhouse' with 40% upside, … Coupon?

Should you buy biontech (bntx)?

Truist initiated coverage of BioNTech (BNTX) with a Buy rating and $172 price target BioNTech is an oncology company “at heart, even though it was the COVID vaccine that made it a household name,” the analyst tells investors in a research note. ...

Is biontech a good stock to buy?

HSBC boosted their price target on BioNTech from $97.00 to $136.00 and gave the stock a “buy” rating in a research note on Monday, October 7th. Finally, Canaccord Genuity Group increased their price objective on BioNTech from $171.00 to $171.44 and gave the company a “buy” rating in a research report on Wednesday, November 27th. ...

Will biontech buy bnt327/pm8002?

With the acquisition, BioNTech will obtain full global rights to the late-stage clinical asset BNT327/PM8002, an investigational bispecific antibody targeting PD-L1 and VEGF-A. Truist initiated with a Buy rating and a price target of $172. BioNTech’s oncology pipeline was previously seen as limited in value outside BNT316. ...

Should you buy biontech se - depositary receipt (bntx)?

Fintel reports that on January 10, 2025, Truist Securities initiated coverage of BioNTech SE - Depositary Receipt () (NasdaqGS:BNTX) with a Buy recommendation. Analyst Price Forecast Suggests 14.22% Upside As of December 23, 2024, the average one-year price target for BioNTech SE - Depositary Receipt () is $139.52/share. ...

What is the average price target for biontech (bntx)?

According to the 14 analysts' twelve-month price targets for BioNTech, the average price target is $135.54. The highest price target for BNTX is $171.00, while the lowest price target for BNTX is $100.00. The average price target represents a forecasted upside of 22.24% from the current price of $110.88. ...

What is the price target for biontech se - depositary receipt ()?

As of December 23, 2024, the average one-year price target for BioNTech SE - Depositary Receipt () is $139.52/share. The forecasts range from a low of $100.23 to a high of $180.02. The average price target represents an increase of 14.22% from its latest reported closing price of $122.15 / share. ...